Alpha-2c-adrenergic receptors contribute to basal nasal patency in the anesthetized cat

Pharmacology

Volumn 85, Issue 5, 2010, Pages 259-263

  Mingo, Garfield G ^a   Corboz, Michel R ^a   Salisbury, Brian G ^a   McCormick, Kevin D ^b   Boyce, Christopher W ^b   Mukhopadhyay, Gitali ^a   McLeod, Robbie L ^a,b  

^a Department of Neurobiology/Respiratory ^*  (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adrenergic receptors; Allergic rhinitis; JP 1302; Nasal patency

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2C ADRENERGIC RECEPTOR; JP 1302; PRAZOSIN; UNCLASSIFIED DRUG; YOHIMBINE; ACRIDINE DERIVATIVE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOPROTEIN; JP-1302; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; COLOR ULTRASOUND FLOWMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; EXPERIMENTAL CAT; MALE; NONHUMAN; NOSE CAVITY; NOSE CONGESTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESPIRATORY FUNCTION; RHINOMETRY; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; ACOUSTIC RHINOMETRY; ADRENERGIC SYSTEM; ANATOMY AND HISTOLOGY; ANESTHESIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CAT; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; NERVE CELL; PHYSIOLOGY; RHINITIS;

ACRIDINES; ADMINISTRATION, INTRANASAL; ADRENERGIC ALPHA-ANTAGONISTS; ANESTHESIA; ANIMALS; BLOOD PRESSURE; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NASAL CAVITY; NEURONS; PIPERAZINES; PROTEIN ISOFORMS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RHINITIS; RHINOMETRY, ACOUSTIC; SYMPATHETIC NERVOUS SYSTEM; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS;

EID: 77950317327     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000284581     Document Type: Article

References (23)

1. Corey JP, Houser SM, Ng BA: Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000; 79: 690-693.
2. Nathan RA, Meltzer EO, Derebery J, Campbell UB, Stang PE, Corrao MA, Allen G, Stanford R: The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008; 29: 600-608.
3. Scadding G: Optimal management of nasal congestion caused by allergic rhinitis in children: safety and efficacy of medical treatments. Paediatr Drugs 2008; 10: 151-162.
4. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C: Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998; 101: 633-637.
5. Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 2007; 357: 1841-1854.
6. Van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, Reiss TF, Montelukast Fall Rhinitis Study Group: Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003; 58: 1268-1276.
7. Nathan RA: The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis. Clin Ther 2008; 30: 573-586.
8. Widdicombe JG: The physiology of the nose. Clin Chest Med 1986; 7: 159-170.
9. Lacroix JS, Lundberg JM: Sympathetic vascular control of the pig nasal mucosa: adrenoceptor mechanisms in blood flow and volume control. Br J Pharmacol 1989; 97: 1075-1084.
10. McLeod RL, Erickson CH, Mingo GG, Hey JA: Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat. Am J Rhinol 2001; 15: 407-415.
11. Corboz MR, Varty LM, Rivelli M, Mutter JC, Mingo GG, McLeod RL, Hey JA: Effect of an2 -adrenoceptor antagonist in nasal mucosa. Arch Physiol Biochem 2003; 111: 335-336.
12. Wang M, Lung MA: Adrenergic mechanisms in canine nasal venous systems. Br J Pharmacol 2003; 138: 145-155.
13. Berkowitz RB, McCafferty F, Dato ME: A proof of concept trial demonstrating decongestant activity of an alpha-2 adrenergic receptor agonist in patient with seasonal allergic rhinitis (SAR). J Allergy Clin Immunol 2005; 115:S127.
14. Stafford-Smith M, Bartz R, Wilson K, Baraniuk JN, Schwinn DA: Alpha-adrenergic mRNA subtype expression in the human nasal turbinate. Can J Anaesth 2007; 54: 549-555.
15. Tricklebank MD: JP-1302: a new tool to shed light on the roles of alpha2C-adrenoceptors in brain. Br J Pharmacol 2007; 50: 381-382.
16. Sallinen J, Hoglund I, Engstrom M, Lehtimaki J, Virtanen R, Sirvio J, Wurster S, Savola JM, Haapalinna A: Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 2007; 50: 391-402.
17. McLeod RL, Mingo GG, Herczku C, Corboz MR, Ramos SI, DeGennaro-Culver F, Pedersen O, Hey JA: Changes in nasal resistance and nasal geometry using pressure and acoustic rhinometry in a feline model of nasal congestion. Am J Rhinol 1999; 13: 375-383.
18. McLeod RL, Mingo GG, Xu X, Palamanda J, Hunter JC, Jia Y: Loratadine and montelukast administered in combination produce decongestion in an experimental feline model of nasal congestion. Am J Rhinol Allergy 2009; 23:e17-e22.
19. Wurster S, Engstrom M, Savola JM, Hoglund L, Sallinen J, Haapalinna A, Hoffren AM: Derivatives of quinoline as alpha-2 antagonists. PCT No WO/2001/064645.
20. Gyires K, Zadori ZS, Torok T, Matyus P: Alpha(2)-adrenoceptor subtypes-mediated physiological, pharmacological actions. Neurochem Int 2009; 55: 447-453.
21. Lacroix JS: Adrenergic and non-adrenergic mechanisms in sympathetic vascular control of the nasal mucosa. Acta Physiol Scand Suppl 1989: 581: 1-63.
22. Corboz MR, Rivelli MA, Mingo GG, McLeod RL, Varty L, Jia Y, Hey JA: Mechanism of decongestant activity of alpha2-adrenoceptor agonists. Pulm Pharmacol Ther 2008; 21: 449-454.
23. Meltzer EO, Berkowitz RB, Grossbard EB: An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005; 115: 791-796.